Develops targeted cancer drug candidates for patients with underserved cancers, using inhibitors, protein degraders and antibody-linked drugs.
10-K for FY2025, filed Mar 10, 2026Prelude Therapeutics Incorporated ("Prelude" or the "Company") is a precision oncology company built on a foundation of drug discovery…View ↗
By focusing on developing molecules using broad mechanisms that have multiple links to oncogenic driver pathways in select patients, we…View ↗
We leverage multiple modalities (inhibitors, degraders, and antibody-drug conjugates) in order to deliver clinical candidates that meet our…View ↗
In 2023, we entered into a multi-year, multi-program agreement with AbCellera Biologics Incorporated ("AbCellera") to jointly discover…View ↗
Prelude receives upfront payments under program option and license agreements; agreements can also provide clinical and regulatory milestone payments and royalties on product sales.
10-K for FY2025, filed Mar 10, 2026
$12.1M
10-K for FY2025, filed Mar 10, 2026
$12.1M ↗No. It lost $99.5M in FY2025.
Pipeline focus
The older report describes programs spanning methyltransferases and protein-protein interactions; the latest emphasizes kinases, targeted protein degraders and degrader antibody conjugates.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 10, 2026By focusing on developing molecules using broad mechanisms that have multiple links to oncogenic driver pathways in select patients, we…View ↗
By focusing on developing molecules using broad mechanisms that have multiple links to oncogenic driver pathways in select patients, we…View ↗
Competes with Ajax Therapeutics, Atavistik Bio, Cogent Biosciences, Eilean Therapeutics, Incyte, Llydlaw Therapeutics, Rathyra Therapeutics, V6 Therapeutics, Pfizer, Olema Oncology, Menarini Group, BeOne Medicines, Ideaya Biosciences, Isosterix, ProtAI, and Beijing Konruns Pharmaceutical
10-K for FY2025, filed Mar 10, 2026For our JAK2V617F inhibitor program, competition includes Ajax Therapeutics, Atavistik Bio, Cogent Biosciences, Eilean Therapeutics, Incyte…View ↗
Loading...